Ma Yingli 4

What Happened Ma Yingli, Chief Technology Officer of Structure Therapeutics (GPCR), received equity awards on 2026-03-19 totaling 72,804 ordinary-share equivalents: 32,526 RSU-type shares and 40,278 derivative shares. Both awards were reported at an acquisition price of $0.00 (company compensation awards), so no cash changed hands on the grant date. The 72,804 ordinary shares equal 24,268 ADSs if converted at 3 ordinary shares per ADS (per footnote).

Key Details

• Transaction date: 2026-03-19; Filing date (Form 4): 2026-03-23 (appears timely).
• Grants: 32,526 RSUs (footnote F2) + 40,278 derivative award units (reported as A/derivative).
• Price: $0.00 per share on grant (compensation award); total cash exchanged on grant = $0.
• Vesting/terms: F2 — the RSUs vest 1/4 annually on each anniversary of March 1, 2026, subject to continued service. F3/F4 — the derivative award references option terms: exercise price equal to fair market value on grant date (F3); vesting of 1/4 on March 1, 2027 with remaining shares vesting in 36 equal monthly installments thereafter (F4), subject to continued service.
• ADS note: Ordinary shares may be represented by ADSs; 3 ordinary shares = 1 ADS (F1).
• Shares owned after transaction: Not specified in the filing.

Context These entries are compensation awards (not open-market purchases or sales). RSUs/derivative awards are common executive compensation and vest over time, so they do not necessarily signal immediate buying or selling intent. The filing includes the award vesting schedules and option terms where applicable; no immediate cashless exercise or sale was reported.